MedTech News

.................... by Andrew Celentano

Cala Announces FDA Clearance of its Next Generation TAPS Therapy Wearable Device for Essential Tremor and Parkinson’s Disease

SAN MATEO, Calif. and CHICAGO, April 15, 2026 /PRNewswire/ — Cala®, the bioelectronic medicine leader, today announced U.S. Food and Drug Administration (FDA) clearance of the Cala kIQ® Plus system, the next-generation of its wearable neurostimulation device for action hand tremor in essential tremor (ET) and Parkinson’s disease (PD). Cala kIQ Plus is the latest advancement in TAPS® technology – introducing new therapy modes and adaptive calibration designed to optimize tremor relief and personalize treatment providing patients with an intuitive experience whenever tremor control is needed.

Read More »

Sign up for Blog Updates